All In Biotech

Drug Trial Radar · NCT07193901

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior

A Randomized, Double-blind, Placebo-controlled Phase Il Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

98

Actual

Start

May 27, 2025

Primary completion

Apr 10, 2026

Study completion Jun 1, 2026

Sponsor

Sponsor type
Industry
First posted
Sep 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about: * To evaluate the efficacy of PRT-042 nasal spray for the Rapid Reduction of the depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior * To evaluate the safety and pharmacokinetic (PK) characteristics after multiple dose of PRT-042 nasal spray in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior

Conditions

  • Major Depressive Disorder (MDD

Interventions

  • Low Dose PRT042 nasal sprayDrug

    two times a week, for 4 weeks

  • median Dose PRT042 nasal sprayDrug

    two times a week, for 4 weeks

  • high dose PRT042 nasal sprayDrug

    two times a week, for 4 weeks

  • placeboDrug

    two times a week, for 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at 24 Hours After the First Dose (Day 2)Time frame: Baseline (Day 1, predose) and 24 hours first post dose (Day 2)

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • The Sixth Hospital of Peking University

    Beijin, China

  • BEIjing AnDing hospital capital medical university

    Beijing, China

  • Beijing Huilongguan Hospital

    Beijing, China

  • Brain Hospital of Hunan Province

    Changsha, China

  • The Second Xiangya Hospital of Central South University

    Changsha, China

  • The Fourth People's Hospital of Chengdu

    Chengdu, China

  • Hangzhou Seventh People's Hospital

    Hangzhou, China

  • Hefei Fourth People's Hospital(Anhui Mental Health Prevention and Treatment Center)

    Hefei, China

  • The fourth affiliated hospital of Anhui medical university

    Hefei, China

  • The Affiliated Hospital of Southwest Medical University

    Luzhou, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China

  • The affiliated Kangning Hospital of Ningbo University

    Ningbo, China

  • Suzhou Guangji Hospital

    Suzhou, China

  • Wuxi Mental Health Center

    Wuxi, China

  • Zhumadian Second People's Hospital(Zhumadian Psychiatric Hospital )

    Zhumadian, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.